HTA Quarterly | Fall 2018

By Xcenda

In this issue, we examine the wearable technology big data revolution from a global perspective, the innovative strategies to provide access for CAR-T therapies, and the considerations for market access in Catalonia. 

HTA QUARTERLY | FALL 2018

Wearing Your Data: A Global Perspective

The global market for wearable technologies is rapidly expanding as mature economies look at ways to more effectively provide healthcare and reduce costs. This article provides a global perspective of wearable technology, describes how the digital streams (“big data”) may be utilized, and contextualizes the wearable technology big data revolution in terms of current health technology assessment (HTA) processes.
3 different wearable technology products

HTA QUARTERLY | FALL 2018

Valuing CAR-T Therapies: Facing New Challenges, Fulfilling the Potential

CAR-T therapies have significant potential to improve health outcomes but also to increase spending on cancer treatments. Determining the value of CAR-T therapies is critical given the high cost of treatment, which has the potential to greatly hinder market access and commercialization of these promising therapies. We examine the regulatory agencies and payer organizations across the global that are exploring and pioneering innovative strategies to mitigate costs and provide access to patients.
cells

HTA QUARTERLY | FALL 2018

Catalonia: Understanding Market Access Within an Autonomous Region in Spain

With a population of 7.5 million people, Catalonia is an autonomous region within Spain in charge of its own healthcare, among other things. The region is considered to be a Spanish economic powerhouse, with a GDP of 234.7 billion Euros in 2017. This particularly holds true for the pharmaceutical sector. Catalonia is the leading biotech region in Spain, and in 2016 was responsible for 43.7% of Spanish pharmaceutical exports. We take a closer look at this unique region.
Catalonia flag

Heard on the Street

“The administration is imposing foreign price controls from countries with socialized health care systems that deny their citizens access and discourage innovation. The proposed Medicare Part B model would jeopardize access to medicines for seniors and patients with disabilities living with devastating conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases.”

– Stephen J. Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) regarding President Trump’s Medicare Part B reform which would implement an International Pricing Index (IPI) payment model.

HTA by the Numbers

$17.2 Billion


Map of Europe

HTA Decision Map

Map of Europe
Find detailed information on product decisions in Australia, Canada, France, Germany, and the United Kingdom with our HTA Decision Map.
Map of Europe